Literature DB >> 10501869

Current surgical therapy for bronchiectasis.

M Ashour1, K Al-Kattan, M A Rafay, K F Saja, W Hajjar, A R Al-Fraye.   

Abstract

The ideal classification system for bronchiectasis continues to be debated. As an alternative to the present morphologic classification, a hemodynamic-based functional classification is proposed. This study examines the rationale for and outcome of surgery based on this classification in patients with unilateral or bilateral bronchiectasis. Between July 1987 and January 1997 the morphologic and hemodynamic features in 85 bronchiectatic patients were examined: 18 with bilateral bronchiectasis and 67 with unilateral disease. A policy of unilateral lung resection of the nonperfused bronchiectasis and preservation of the perfused type was adopted in all patients. The mean age at operation was 29.4 +/- 9.7 years (range 6-55 years) with a mean follow-up period of 45.2 +/- 21.0 months (range 2-120 months). Left-sided predominance of bronchiectasis was evident in this series both in frequency and severity. In those with unilateral disease, bronchiectasis was left-sided in 49 (73.1%) patients and right-sided in 18 (26.9%). The left lung was totally bronchiectatic in 11 (16.4%) patients and the right in 3 (4.4%). Moreover, among the patients with bilateral bronchiectasis, 14 of 18 (77.7%) patients had the left lung more severely involved. Based on the morphologic and hemodynamic features in the investigated patients, two types of bronchiectasis were recognized: a perfused type with intact pulmonary artery flow and a nonperfused type with absent pulmonary artery flow. Lobectomy was performed in 55 patients, basal segmentectomy and preservation of the apical segment in 16, and pneumonectomy in 14. There was no mortality in this series. Altogether 63 patients (74.1%) achieved excellent results, 19 (22.4%) scored good results, and 3 (3.5%) patients had not benefited from surgery at last follow-up. In the face of the general criticism of the traditional morphologic classification, the proposed classification not only predicts whether the involved lung will have a measure of respiratory function with regard to gas exchange but reflects the degree of severity of the disease process. Thus the question of which side to resect and which to preserve is defined more precisely. This classification was found to be logical, physiologically sound, and of proven benefit.

Entities:  

Mesh:

Year:  1999        PMID: 10501869     DOI: 10.1007/s002689900630

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  9 in total

1.  Surgical treatment of bronchiectasis: a retrospective observational study of 138 patients.

Authors:  Reda E Al-Refaie; Sameh Amer; Mohamed El-Shabrawy
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Surgical management of bronchiectasis: the indications and outcomes.

Authors:  Soner Gursoy; Ali Ata Ozturk; Ahmet Ucvet; Ahmet Emin Erbaycu
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

3.  End-stage localized bronchiectasis mimicking a hemangioma.

Authors:  Sayaka Otani; Shunsuke Endo; Hiroyoshi Tsubochi; Mitsuhiro Nokubi; Shinichiro Koyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-12

4.  A long-term study assessing the factors influencing survival and morbidity in the surgical management of bronchiectasis.

Authors:  Abidin Sehitogullari; Salim Bilici; Fuat Sayir; Ufuk Cobanoglu; Ali Kahraman
Journal:  J Cardiothorac Surg       Date:  2011-12-11       Impact factor: 1.637

5.  Protective effect of angiotensin-(1-7) against hyperglycaemia-induced injury in H9c2 cardiomyoblast cells via the PI3K̸Akt signaling pathway.

Authors:  Yi-Ying Yang; Xiu-Ting Sun; Zheng-Xun Li; Wei-Yan Chen; Xiang Wang; Mei-Ling Liang; Hui Shi; Zhi-Sheng Yang; Wu-Tao Zeng
Journal:  Int J Mol Med       Date:  2017-12-15       Impact factor: 4.101

6.  Angiotensin-(1-7) protects cardiomyocytes against high glucose-induced injuries through inhibiting reactive oxygen species-activated leptin-p38 mitogen-activated protein kinase/extracellular signal-regulated protein kinase 1/2 pathways, but not the leptin-c-Jun N-terminal kinase pathway in vitro.

Authors:  Yiyan Lei; Qing Xu; Bo Zeng; Wei Zhang; Yulan Zhen; Yuansheng Zhai; Fei Cheng; Weiyi Mei; Dongdan Zheng; Jianqiang Feng; Jun Lan; Jingfu Chen
Journal:  J Diabetes Investig       Date:  2017-02-28       Impact factor: 4.232

7.  Uniportal thoracoscopic treatment in bronchiectasis patients: preliminary experience.

Authors:  Ilhan Ocakcioglu
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-10-15       Impact factor: 1.195

8.  Surgical treatment of bronchiectasis: Our 23 years of experience.

Authors:  Selim Şakir Erkmen Gülhan; Leyla Nesrin Acar; Ebru Sayılır Güven; Pınar Bıçakçıoğlu; Ertan Aydın; Sezgin Karasu; Abdullah İrfan Taştepe; Funda İncekara; Sadi Kaya; Göktürk Fındık
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-10-21       Impact factor: 0.332

9.  Survival of bronchiectatic patients with respiratory failure in ICU.

Authors:  Abdulaziz H Alzeer; Mohammed Masood; Syed Jani Basha; Shaffi A Shaik
Journal:  BMC Pulm Med       Date:  2007-12-10       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.